Press Release: Novartis IgAN data in The Lancet -2-

forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Heerspink HJL, et al. Final 2.5--year results from the Phase III ALIGN

study in IgA nephropathy. Presented at the European Renal Association

(ERA) Congress; June 2026; Glasgow, U.K.

2. Heerspink HJL, Jardine MJ, Kohan DE, et al. Atrasentan in patients with

IgA nephropathy: final 2.5--year results from the randomised,

double--blind, placebo--controlled phase 3 ALIGN trial. The Lancet.

Published online June 4, 2026.

3. Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with

IgA nephropathy. New England Journal of Medicine. 2025; 392(6): 544--554.

4. Heerspink HJL, Noronha IL, Gorriz J, et al. Efficacy and safety of

atrasentan in patients with IgA nephropathy receiving sodium-glucose

cotransporter 2 inhibitors: placebo-controlled, crossover trial. Journal

of the American Society of Nephrology. 2026.

5. Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated

approval for Vanrafia(R) (atrasentan), the first and only selective

endothelin A receptor antagonist for proteinuria reduction in primary IgA

nephropathy (IgAN). Available at:

https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan.

Accessed in May 2026.

6. Novartis China. Novartis innovative medicine Vanrafia(R) (atrasentan)

approved in China for IgA nephropathy. Available at:

https://www.novartis.com.cn/news/nuohuachuangxinyaowunuoruidayansuanaqushengtanpianigashenbingshiyingzhengzaizhongguohuopi.

Accessed in May 2026.

7. Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement

proteins as a target for therapy of IgA nephropathy. Frontiers in

Immunology. 2019;10:504.

8. Cheung CK, Barratt J. The rapidly changing treatment landscape of IgA

nephropathy. Seminars in Nephrology. 2025;44(5):151573.

9. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of

the epidemiology, health-related quality of life impact, and economic

burden of immunoglobulin a nephropathy. Journal of Health Economics and

Outcomes Research. 2021;8(2):36--45.

10. Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN.

Clinical Journal of the American Society of Nephrology. 2023;18:727--8.

11. Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of

immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One.

2021;16(4):e0249592

12. National Kidney Foundation. The voice of the patient. 2020. Available at:

https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf.

Accessed May 2026.

13. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases

Work Group. KDIGO 2021 clinical practice guideline for the management of

glomerular diseases. Kidney International. 2021;100(suppl 1):S1--S276.

14. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway

inhibition with iptacopan in IgA nephropathy. New England Journal of

Medicine. 2025;392:531--543.

15. ClinicalTrials.gov. NCT04573478. A phase 3 randomized study of atrasentan

in patients with IgA nephropathy at risk of progressive loss of renal

function. Available at https://clinicaltrials.gov/study/NCT04573478.

Accessed May 2026.

16. Barratt J, Kim SG, Inker LA et al. AFFINITY study: 1-year results of

atrasentan in IgA nephropathy. Journal of the American Society of

Nephrology. 2024;35(10 suppl):720. Abstract FR--PO855.

17. Heerspink HJL, Jardine M, Kohan DE et al. Study design and baseline

characteristics of ALIGN, a randomized controlled study of atrasentan in

patients with IgA nephropathy. Kidney International Reports.

2024;10:217--226.

18. Kohan DE, Barratt J, Heerspink HJL et al. Targeting the endothelin A

receptor in IgA nephropathy. Kidney International Reports.

2023;8:2198--2210.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 04, 2026 06:15 ET (10:15 GMT)